Table 2.
Clinical evolution during hospitalization between the study groups.
| I group (n = 35) | LI group (n = 34) | p value | |
|---|---|---|---|
| Days in hospital | 12 ± 1 | 10 ± 1 | 0.343 |
| Assisted mechanical ventilation n (%) | 12 (34.3) | 3 (8.8) | 0.010 |
| Days from hospital admission to mechanical ventilation | 4.5 ± 1.0 | 5.0 ± 1.5 | 0.749 |
| Mortality, n (%) | 6 (17.1) | 2 (5.9) | 0.139 |
| Average glucose (mg/dl) | 152 ± 3 | 141 ± 2 | 0.008 |
| Last fasting glucose (mg/dl) | 149 ± 10 | 122 ± 7 | 0.033 |
| Last postprandial glucose (mg/dl) | 173 ± 12 | 137 ± 7 | 0.017 |
| Hypoglycemic events, n | 13 | 11 | |
| PaO2/FiO2 (mmHg/%) | 174 ± 12 | 175 ± 12 | 0.981 |
| Prone position, n (%) | 23 (74) | 22 (73) | 0.939 |
| Vasopressor amines, n (%) | 8 (29) | 9 (30) | 0.905 |
| Acute renal failure, n (%) | 6 (17) | 7 (20) | 0.678 |
| SOFA score | 2.7 ± 0.2 | 2.5 ± 0.2 | 0.495 |
| APACHEII score | 10.9 ± 1.0 | 9.8 ± 1.0 | 0.385 |
| Main symptoms, n (%) | |||
| Cought | 19 (54) | 16 (47) | 0.491 |
| Dysnea | 26 (74) | 21 (62) | 0.117 |
| Fever | 13 (37) | 16 (47) | 0.438 |
| Cephalea | 11 (31) | 10 (29) | 0.787 |
| Anosmia | 2 | 3 | 0.500 |
| Previous treatment, n (%) | |||
| Ivermectin | 4 (11) | 4 (11) | 0.960 |
| Treatment, n (%) | |||
| Antibiotics | 12 (34) | 11 (32) | 0.590 |
| Dexamethasone | 35 (100) | 34 (100) | 1.000 |
| Anticoagulant | 35 (100) | 34 (100) | 1.000 |
| CRP (mg/L) | 72 ± 20 | 46 ± 15 | 0.334 |
Data are mean ± SEM.
PaO2/FiO2 ratio between partial pressure of arterial oxygen and fraction of inspired oxygen, SOFA sequential organ failure assessment score, CRP C reactive protein.